Eldehna, Wagdy, Alkabbani, Mahmoud Abdelrahman, Ammara, Andrea, Dahab, Mohammad, Al-Warhi, Tarfah, Elkotamy, Mahmoud S., Elimam, Diaaeldin M., Afarinkia, Kamyar ORCID: https://orcid.org/0000-0003-2819-4364, Elkady, Hazem, Elbadawi, Mostafa M., Nocentini, Alessio, Supuran, Claudiu T. and Tawfik, Haytham O.
(2026)
Design, synthesis, and biological evaluation of isatin-based
benzenesulfonamides as carbonic anhydrase II/VII inhibitors with anticonvulsant activity.
European Journal of Medicinal Chemistry, 321.
ISSN 0223-5234
|
PDF
EJMECH-119433.pdf - Draft Version Restricted to Repository staff only Download (12MB) |
Abstract
Epilepsy remains a challenging neurological disorder, with a significant proportion of patients exhibiting resistance to current antiseizure medications. Herein, we report the rational design, synthesis, and biological evaluation of a new series of isatin thiazolidine-2,4-dione hybrids bearing a pendant benzenesulfonamide moiety as potential antiepileptic agents targeting epilepsy-associated carbonic anhydrase isoforms II and VII. The molecular design integrates key pharmacophoric features shared by established anticonvulsants, including dual aromatic systems, hydrogen-bond donor/acceptor functionalities, and electron-donating groups, and combines them with a sulfonamide zinc-binding motif to enable carbonic anhydrase inhibition. Several compounds exhibited promising nanomolar inhibitory activity against hCA II and hCAVII, with compounds 4c,6a,6d,and6eprioritizedfor in vivo screening based on their combined hCA II/VII inhibition and selectivity over hCA I. Among them, compound 6a showed the strongest phenotypic anticonvulsant activity, providing complete protection in the PTZ model and, in the pilocarpine model, delaying seizure onset, reducing severity, and improving survival. Molecular docking and molecular dynamics simulations provided structural insights into the binding mode and dynamic behavior of compound 6a within the active sites of hCA II and hCA VII, complementing the experimentally determined enzyme inhibition data. Collectively, these results highlight isatin-thiazolidine-2,4-dione-benzenesulfonamide hybrids as a promising scaffold for the development of new antiepileptic agents.
| Item Type: | Article |
|---|---|
| Identifier: | 10.1016/j.ejmech.2026.119433 |
| Keywords: | Thiazolidine-2,4-dione; Benzenesulfonamide; Isatin; Antiepileptic agents; In vivo; In silico |
| Subjects: | Medicine and health > Microbiology Medicine and health > Clinical medicine |
| Date Deposited: | 24 Oct 2026 |
| Dates: | Date Publication status 13 October 2026 Accepted 17 October 2026 Published Online 21 October 2026 Published |
| School, department or research centre: | School of Medicine and Biosciences |
| Keywords: | Thiazolidine-2,4-dione; Benzenesulfonamide; Isatin; Antiepileptic agents; In vivo; In silico |
| URI: | https://repository.uwl.ac.uk/id/eprint/15553 |
Actions (admin access)
![]() |
Lists
Lists